학술논문

Endocardial versus epicardial left atrial appendage exclusion for stroke prevention in patients with atrial fibrillation: Midterm follow‐up.
Document Type
Article
Source
Journal of Cardiovascular Electrophysiology. Jan2021, Vol. 32 Issue 1, p93-101. 9p. 2 Diagrams, 2 Charts.
Subject
*STROKE prevention
*AGE distribution
*ANTICOAGULANTS
*ATRIAL arrhythmias
*ATRIAL fibrillation
*COMPARATIVE studies
*ENDOCARDIUM
*CARDIAC surgery
*HEART failure
*PATIENT aftercare
*SCIENTIFIC observation
*ORAL drug administration
*PERIPHERAL vascular diseases
*SEX distribution
*TRANSIENT ischemic attack
*RETROSPECTIVE studies
*CASE-control method
*DESCRIPTIVE statistics
*LEFT heart atrium
PERICARDIUM surgery
Language
ISSN
1045-3873
Abstract
Background: Left atrial appendage closure (LAAC) became an alternative method for stroke prevention in patients with non‐valvular atrial fibrillation (AF) intolerant to long term oral anticoagulation therapy. This study aimed to compare endocardial (Amulet and LAmbere occluders) and epicardial (Lariat) LAAC techniques. Methods: A retrospective, observational case‐control study included 223 consecutive CHA2DS2‐VAS score–matched patients with AF who underwent LAAC in two centers. Results: There were 55 matched cases with the mean CHA2DS2‐VASs score 4.4 ± 1.22 (p = 1). Overall follow‐up was 308.2 patient‐years. The Endocardial group patients were older and more often females with congestive heart failure and peripheral vascular disease. The epicardial group more frequently had a stroke/transient ischemic attack history. There were no differences in hypertension, diabetes mellitus, and indications for procedure between both groups. The mean HAS‐BLED score was significantly higher in the endocardial group than in the epicardial group (4.3 ± 0.9 vs. 3.7 ± 1.3, p =.011). There were no differences in annual rates of thromboembolic events (2.6% vs 0.5%) and annual stroke (0.87% vs. 0%) between the endocardial and epicardial groups. Conclusion: Endocardial and Epicardial LAAC techniques show comparable implantation outcomes and safety profile and stroke prevention in patients with AF. Future randomized studies are needed to corroborate these initial results and assess long term mortality. [ABSTRACT FROM AUTHOR]